Children with lupus nephritis who receive belimumab achieve treatment targets faster, and can taper glucocorticoids earlier, than those using standard immunotherapy, according to data published in ...

Enhancing clinical research in India with publicly accessible histopathological image datasets for cancer and kidney disease ...

Hyderabad: IIIT Hyderabad, in collaboration with Nizam's Institute of Medical Sciences (NIMS), has released digitised ...

Hyderabad:IIIT Hyderabad (IIIT-H) and Nizam’s Institute of Medical Sciences (NIMS) have launched India’s first publicly ...

Objectives SLE is a multifaceted autoimmune disorder with a complex pathogenesis involving genetic, environmental and ...

Caribou Biosciences has launched a Phase 1 trial testing its CAR T-cell therapy CB-010 for lupus affecting the kidneys and ...

The Phase 1 GALLOP study evaluating the investigational therapy, CB-010, for treatment of lupus nephritis has launched.

Kyverna Therapeutics, Inc. (Kyverna, NASDAQ: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced it will present its ...

About 100 days into the CEO role at Kyverna Therapeutics, Warner Biddle has determined the strategic priorities for the ...

Caribou has initiated the GALLOP Phase 1 clinical trial, an open-label, multicenter clinical trial designed to evaluate a single infusion of CB-010 in adult patients with LN and ERL. CB-011, a ...

Caribou Biosciences (CRBU) announced initiation of the GALLOP Phase 1 clinical trial evaluating CB-010 in patients with lupus nephritis and ...

to assess therapies for initial management of lupus nephritis (LN), focusing on their design with study populations and outcomes, examining the results and identifying gaps that should be addressed in ...